| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Biological, clinical and population relevance of 95 loci for blood lipids.
|
Nature
|
2010
|
28.21
|
|
2
|
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease.
|
Nat Genet
|
2011
|
13.25
|
|
3
|
Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.
|
Circulation
|
2006
|
6.17
|
|
4
|
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.
|
Lancet
|
2010
|
5.31
|
|
5
|
Genetic variants influencing circulating lipid levels and risk of coronary artery disease.
|
Arterioscler Thromb Vasc Biol
|
2010
|
4.08
|
|
6
|
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
|
Lancet
|
2010
|
4.07
|
|
7
|
Lipid-related markers and cardiovascular disease prediction.
|
JAMA
|
2012
|
3.91
|
|
8
|
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
|
J Am Coll Cardiol
|
2012
|
3.66
|
|
9
|
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals.
|
PLoS Genet
|
2012
|
3.21
|
|
10
|
Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study.
|
Circulation
|
2007
|
3.20
|
|
11
|
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
|
Circulation
|
2011
|
3.01
|
|
12
|
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
|
J Am Coll Cardiol
|
2008
|
2.51
|
|
13
|
Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women.
|
J Am Coll Cardiol
|
2009
|
2.50
|
|
14
|
Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events?
|
Arch Intern Med
|
2008
|
2.30
|
|
15
|
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
|
Circulation
|
2008
|
2.30
|
|
16
|
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
|
J Am Coll Cardiol
|
2007
|
2.29
|
|
17
|
Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.
|
Ann Intern Med
|
2007
|
2.26
|
|
18
|
Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study.
|
J Am Coll Cardiol
|
2007
|
2.22
|
|
19
|
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.
|
J Am Coll Cardiol
|
2013
|
2.18
|
|
20
|
Hybrid myocardial perfusion SPECT/CT coronary angiography and invasive coronary angiography in patients with stable angina pectoris lead to similar treatment decisions.
|
Heart
|
2012
|
2.05
|
|
21
|
Red cell distribution width is associated with physical inactivity and heart failure, independent of established risk factors, inflammation or iron metabolism; the EPIC-Norfolk study.
|
Int J Cardiol
|
2013
|
2.05
|
|
22
|
High-density lipoprotein particle size and concentration and coronary risk.
|
Ann Intern Med
|
2009
|
2.02
|
|
23
|
Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study.
|
Heart
|
2010
|
1.91
|
|
24
|
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.
|
Circulation
|
2012
|
1.76
|
|
25
|
Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility.
|
Circulation
|
2010
|
1.75
|
|
26
|
Serum levels of mannose-binding lectin and the risk of future coronary artery disease in apparently healthy men and women.
|
Arterioscler Thromb Vasc Biol
|
2006
|
1.62
|
|
27
|
The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study.
|
CMAJ
|
2010
|
1.45
|
|
28
|
Lipid parameters for measuring risk of cardiovascular disease.
|
Nat Rev Cardiol
|
2011
|
1.43
|
|
29
|
Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study.
|
Eur Heart J
|
2013
|
1.41
|
|
30
|
C-reactive protein is a mediator of cardiovascular disease.
|
Eur Heart J
|
2010
|
1.38
|
|
31
|
ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk.
|
Arterioscler Thromb Vasc Biol
|
2008
|
1.34
|
|
32
|
The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.
|
Eur Heart J
|
2014
|
1.34
|
|
33
|
Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study.
|
Arterioscler Thromb Vasc Biol
|
2007
|
1.34
|
|
34
|
Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.
|
J Am Coll Cardiol
|
2010
|
1.34
|
|
35
|
Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women.
|
Eur Heart J
|
2009
|
1.31
|
|
36
|
Inherited disorders of HDL metabolism and atherosclerosis.
|
Curr Opin Lipidol
|
2005
|
1.29
|
|
37
|
Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study.
|
J Lipid Res
|
2006
|
1.28
|
|
38
|
Apolipoprotein A-II is inversely associated with risk of future coronary artery disease.
|
Circulation
|
2007
|
1.23
|
|
39
|
HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.
|
Atherosclerosis
|
2009
|
1.21
|
|
40
|
Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.
|
Circulation
|
2009
|
1.20
|
|
41
|
PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry.
|
Circulation
|
2010
|
1.14
|
|
42
|
Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.
|
Circulation
|
2002
|
1.13
|
|
43
|
The role of non-HDL cholesterol in risk stratification for coronary artery disease.
|
Curr Atheroscler Rep
|
2012
|
1.11
|
|
44
|
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
|
J Am Coll Cardiol
|
2012
|
1.11
|
|
45
|
Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women.
|
J Clin Endocrinol Metab
|
2008
|
1.10
|
|
46
|
Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.
|
J Lipid Res
|
2011
|
1.09
|
|
47
|
Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study.
|
Arterioscler Thromb Vasc Biol
|
2005
|
1.08
|
|
48
|
Gene polymorphisms and the risk of myocardial infarction--an emerging relation.
|
N Engl J Med
|
2002
|
1.07
|
|
49
|
Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study.
|
Arterioscler Thromb Vasc Biol
|
2012
|
1.04
|
|
50
|
Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study.
|
Eur Heart J
|
2007
|
1.04
|
|
51
|
Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study.
|
J Lipid Res
|
2006
|
1.03
|
|
52
|
Retracted
Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.
|
J Am Coll Cardiol
|
2012
|
1.01
|
|
53
|
The relationship between plasma angiopoietin-like protein 4 levels, angiopoietin-like protein 4 genotype, and coronary heart disease risk.
|
Arterioscler Thromb Vasc Biol
|
2010
|
1.00
|
|
54
|
Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003.
|
Arterioscler Thromb Vasc Biol
|
2009
|
0.97
|
|
55
|
Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
|
Arterioscler Thromb Vasc Biol
|
2006
|
0.94
|
|
56
|
Polymorphisms in APOA1 and LPL genes are statistically independently associated with fasting TG in men with CAD.
|
Eur J Hum Genet
|
2005
|
0.93
|
|
57
|
Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study.
|
PLoS One
|
2009
|
0.93
|
|
58
|
Physical activity, the Framingham risk score and risk of coronary heart disease in men and women of the EPIC-Norfolk study.
|
Atherosclerosis
|
2009
|
0.92
|
|
59
|
Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT.
|
Atherosclerosis
|
2010
|
0.90
|
|
60
|
C-reactive protein, fatal and nonfatal coronary artery disease, stroke, and peripheral artery disease in the prospective EPIC-Norfolk cohort study.
|
Arterioscler Thromb Vasc Biol
|
2013
|
0.89
|
|
61
|
Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.
|
Int J Cardiol
|
2009
|
0.87
|
|
62
|
Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study).
|
Am J Cardiol
|
2011
|
0.86
|
|
63
|
Physical activity, metabolic syndrome, and coronary risk: the EPIC-Norfolk prospective population study.
|
Eur J Cardiovasc Prev Rehabil
|
2011
|
0.86
|
|
64
|
Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia.
|
Eur J Hum Genet
|
2005
|
0.86
|
|
65
|
Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size.
|
Clin Chem
|
2010
|
0.86
|
|
66
|
Lipid assessment, metabolic syndrome and coronary heart disease risk.
|
Eur J Clin Invest
|
2010
|
0.85
|
|
67
|
Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?
|
Circulation
|
2008
|
0.84
|
|
68
|
Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study.
|
Eur J Clin Invest
|
2013
|
0.84
|
|
69
|
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies.
|
Circ Cardiovasc Genet
|
2011
|
0.84
|
|
70
|
Chemokine ligand 2 genetic variants, serum monocyte chemoattractant protein-1 levels, and the risk of coronary artery disease.
|
Arterioscler Thromb Vasc Biol
|
2010
|
0.83
|
|
71
|
Major depression, C-reactive protein, and incident ischemic heart disease in healthy men and women.
|
Psychosom Med
|
2008
|
0.83
|
|
72
|
Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women.
|
Circ Cardiovasc Genet
|
2009
|
0.82
|
|
73
|
Varespladib: targeting the inflammatory face of atherosclerosis.
|
Eur Heart J
|
2010
|
0.80
|
|
74
|
Incremental diagnostic accuracy of hybrid SPECT/CT coronary angiography in a population with an intermediate to high pre-test likelihood of coronary artery disease.
|
Eur Heart J Cardiovasc Imaging
|
2013
|
0.80
|
|
75
|
High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect.
|
Circulation
|
2013
|
0.79
|
|
76
|
High-sensitivity troponin T is associated with poor outcome in adults with pulmonary arterial hypertension due to congenital heart disease.
|
Congenit Heart Dis
|
2012
|
0.79
|
|
77
|
A comparative analysis of three widely used lipid management guidelines in the EPIC-Norfolk cohort.
|
Eur J Prev Cardiol
|
2012
|
0.79
|
|
78
|
Relationship between atorvastatin dose and the harm caused by torcetrapib.
|
J Lipid Res
|
2012
|
0.79
|
|
79
|
Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model.
|
BMC Med
|
2012
|
0.79
|
|
80
|
Thrombospondin gene polymorphisms and the risk of angiographic coronary in-stent restenosis.
|
Am J Med
|
2004
|
0.78
|
|
81
|
Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels.
|
Circ Cardiovasc Genet
|
2014
|
0.78
|
|
82
|
Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?
|
Curr Opin Cardiol
|
2010
|
0.78
|
|
83
|
Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention.
|
Pharmacogenet Genomics
|
2010
|
0.78
|
|
84
|
Non-high-density lipoprotein cholesterol: current status as cardiovascular marker.
|
Curr Opin Lipidol
|
2015
|
0.78
|
|
85
|
Usefulness of coronary calcium scoring to myocardial perfusion SPECT in the diagnosis of coronary artery disease in a predominantly high risk population.
|
Int J Cardiovasc Imaging
|
2012
|
0.77
|
|
86
|
De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough?
|
Eur Heart J
|
2011
|
0.76
|
|
87
|
Relationship between in vitro lipopolysaccharide-induced cytokine response in whole blood, angiographic in-stent restenosis, and toll-like receptor 4 gene polymorphisms.
|
Clin Chem
|
2005
|
0.76
|
|
88
|
Response to letter by Balta et al.
|
Int J Cardiol
|
2013
|
0.75
|
|
89
|
Prospective study of insulin-like growth factor-I, insulin-like growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease.
|
Int J Mol Epidemiol Genet
|
2011
|
0.75
|
|
90
|
Reply: statin-induced low low-density lipoprotein cholesterol level: is lower better?
|
J Am Coll Cardiol
|
2015
|
0.75
|
|
91
|
The authors’ reply.
|
Heart
|
2013
|
0.75
|
|
92
|
Reply: To PMID 23219296.
|
J Am Coll Cardiol
|
2013
|
0.75
|
|
93
|
Improving risk stratification for cardiovascular disease.
|
Expert Rev Cardiovasc Ther
|
2010
|
0.75
|
|
94
|
Dilation of the Aorta Ascendens Forms Part of the Clinical Spectrum of HCN4 Mutations.
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
95
|
Clinical and biological relevance of statin-mediated changes in HDL metabolism.
|
Curr Atheroscler Rep
|
2014
|
0.75
|
|
96
|
Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms.
|
J Am Coll Cardiol
|
2017
|
0.75
|
|
97
|
IgM antibodies against apoptotic cells and phosphorylcholine in patients with acute myocardial infarction in relation to infarct size and inflammatory response.
|
Adv Clin Exp Med
|
2012
|
0.75
|
|
98
|
Coronary Artery Disease Affects Symptomatology of Aortic Valve Stenosis.
|
J Am Coll Cardiol
|
2017
|
0.75
|
|
99
|
Rates and determinants of progressive aortic valve dysfunction in aortic coarctation.
|
Int J Cardiol
|
2012
|
0.75
|
|
100
|
Impact of abdominal obesity and systemic hypertension on risk of coronary heart disease in men and women: the EPIC-Norfolk Population Study.
|
J Hypertens
|
2014
|
0.75
|